University of Rochester School of Medicine & Dentistry, Rochester, NY, USA.
Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
J Alzheimers Dis. 2021;82(3):921-937. doi: 10.3233/JAD-210434.
APOEɛ4 allele carriers present with an increased risk for late-onset Alzheimer's disease (AD), show cognitive symptoms at an earlier age, and are more likely to transition from mild cognitive impairment (MCI) to dementia but despite this, it remains unclear whether or not the ɛ4 allele controls the rate of disease progression.
To determine the effects of the ɛ4 allele on rates of cognitive decline and brain atrophy during MCI and dementia stages of AD.
A segmented linear mixed model was chosen for longitudinal modeling of cognitive and brain volumetric data of 73 ɛ3/ɛ3, 99 ɛ3/ɛ4, and 39 ɛ4/ɛ4 Alzheimer's Disease Neuroimaging Initiative participants who transitioned during the study from MCI to AD dementia.
ɛ4 carriers showed faster decline on MMSE, ADAS-11, CDR-SB, and MoCA scales, with the last two measures showing significant ɛ4 allele-dose effects after dementia transition but not during MCI. The ɛ4 effect was more prevalent in younger participants and in females. ɛ4 carriers also demonstrated faster rates of atrophy of the whole brain, the hippocampus, the entorhinal cortex, the middle temporal gyrus, and expansion of the ventricles after transitioning to dementia but not during MCI.
Possession of the ɛ4 allele is associated with a faster progression of dementia due to AD. Our observations support the notion that APOE genotype not only controls AD risk but also differentially regulates mechanisms of neurodegeneration underlying disease advancement. Furthermore, our findings carry significance for AD clinical trial design.
APOEɛ4 等位基因携带者患晚期阿尔茨海默病(AD)的风险增加,发病年龄更早,更有可能从轻度认知障碍(MCI)发展为痴呆,但尽管如此,尚不清楚ɛ4 等位基因是否控制疾病进展的速度。
确定ɛ4 等位基因对 AD 的 MCI 和痴呆阶段认知下降和脑萎缩速度的影响。
选择分段线性混合模型对 73 名ɛ3/ɛ3、99 名ɛ3/ɛ4 和 39 名ɛ4/ɛ4阿尔茨海默病神经影像学倡议参与者的认知和脑容量数据进行纵向建模,这些参与者在研究期间从 MCI 进展为 AD 痴呆。
ɛ4 携带者在 MMSE、ADAS-11、CDR-SB 和 MoCA 量表上的下降速度更快,后两项指标在痴呆转变后但在 MCI 期间表现出明显的ɛ4 等位基因剂量效应。ɛ4 效应在年轻参与者和女性中更为普遍。ɛ4 携带者在向痴呆转变后也表现出全脑、海马体、内嗅皮质、颞中回和脑室扩张更快的萎缩速度,但在 MCI 期间没有。
携带ɛ4 等位基因与 AD 导致的痴呆进展更快有关。我们的观察结果支持这样一种观点,即 APOE 基因型不仅控制 AD 风险,而且还差异调节导致疾病进展的神经退行性变机制。此外,我们的研究结果对 AD 临床试验设计具有重要意义。